Abliva   Report issue

For profit Phase 1 Phase 2
Founded: Lund Sweden (2000)

Organization Overview

First Clinical Trial
2009
NCT01692834
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Abliva AB | NeuroVive Pharmaceutical AB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

MELAS Syndrome (Phase 1)

Mitochondrial Diseases (Phase 1)

Mitochondrial Myopathies (Phase 1)

Muscular Diseases (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 9